
## Jason L Eriksen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7922795/publications.pdf Version: 2024-02-01



LASON L EDIKSEN

#	Article	IF	CITATIONS
1	1â€Indanone and 1,3â€Indandione Derivatives as Ligands for Misfolded αâ€5ynuclein Aggregates. ChemMedChem, 2022, 17, e202100611.	1.6	5
2	Prostacyclin Promotes Degenerative Pathology in a Model of Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2022, 16, 769347.	1.8	1
3	Cycad Genotoxin Methylazoxymethanol Disrupts the Brain Ubiquitin-Proteasome Pathway, Tau and α-Synuclein, as Reported in ALS-PDC. Journal of Neuropathology and Experimental Neurology, 2021, 80, 286-288.	0.9	4
4	Exercise training ameliorates cerebrovascular dysfunction in a murine model of Alzheimer's disease: role of the P2Y2 receptor and endoplasmic reticulum stress. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H1559-H1569.	1.5	13
5	Segmenting Continuous but Sparsely-Labeled Structures in Super-Resolution Microscopy Using Perceptual Grouping. Lecture Notes in Computer Science, 2020, , 141-150.	1.0	1
6	Multiplex protein-specific microscopy with ultraviolet surface excitation. Biomedical Optics Express, 2020, 11, 99.	1.5	10
7	Effects of Prostacyclin Signaling on Alzheimer's Disease Associated Pathologies. FASEB Journal, 2020, 34, 1-1.	0.2	0
8	Three-Dimensional Microscopy by Milling with Ultraviolet Excitation. Scientific Reports, 2019, 9, 14578.	1.6	17
9	Robust Tracing and Visualization of Heterogeneous Microvascular Networks. IEEE Transactions on Visualization and Computer Graphics, 2019, 25, 1760-1773.	2.9	8
10	7B2 chaperone knockout in APP model mice results in reduced plaque burden. Scientific Reports, 2018, 8, 9813.	1.6	3
11	Plasmonic nanoparticle-based expansion microscopy with surface-enhanced Raman and dark-field spectroscopic imaging. Biomedical Optics Express, 2018, 9, 603.	1.5	17
12	Hyperspectral expansion microscopy. , 2017, , .		2
13	A Novel Liposomal Nanoparticle for the Imaging of Amyloid Plaque by Magnetic Resonance Imaging. Journal of Alzheimer's Disease, 2016, 52, 731-745.	1.2	31
14	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
15	Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 1029-1034.	1.4	35
16	Formaldehyde scavengers function as novel antigen retrieval agents. Scientific Reports, 2015, 5, 17322.	1.6	6
17	Long-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice. Molecular Neurodegeneration, 2014, 9, 54.	4.4	72
18	Regular exercise prevents non-cognitive disturbances in a rat model of Alzheimer's disease. International Journal of Neuropsychopharmacology, 2014, 17, 593-602.	1.0	32

JASON L ERIKSEN

#	Article	IF	CITATIONS
19	A novel function for pro <scp>SAAS</scp> as an amyloid antiâ€aggregant in Alzheimer's disease. Journal of Neurochemistry, 2014, 128, 419-430.	2.1	44
20	Elevated prostacyclin biosynthesis in mice impacts memory and anxiety-like behavior. Behavioural Brain Research, 2014, 258, 138-144.	1.2	7
21	Microglia in the Alzheimers brain: a help or a hindrance?. AIMS Neuroscience, 2014, 1, 210-224.	1.0	0
22	Chronic treatment with DCPCX, an adenosine A1 antagonist, worsens long-term memory. Neuroscience Letters, 2013, 548, 296-300.	1.0	22
23	β <sub>2</sub> -Adrenoceptor Agonists Are Required for Development of the Asthma Phenotype in a Murine Model. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 220-229.	1.4	53
24	Inhibitory Neuron and Hippocampal Circuit Dysfunction in an Aged Mouse Model of Alzheimer's Disease. PLoS ONE, 2013, 8, e64318.	1.1	73
25	The Neuroendocrine Protein 7B2 Suppresses the Aggregation of Neurodegenerative Disease-related Proteins. Journal of Biological Chemistry, 2013, 288, 1114-1124.	1.6	47
26	Therapeutic Targets in the Ubiquitin-proteasome System for Alzheimer's Disease. Current Enzyme Inhibition, 2013, 9, 46-54.	0.3	1
27	Treadmill Exercise Prevents Learning and Memory Impairment in Alzheimer's Disease-Like Pathology. Current Alzheimer Research, 2013, 10, 507-515.	0.7	83
28	Editorial (Hot Topic Therapeutic Targets in Neurodegenerative Diseases). Current Enzyme Inhibition, 2013, 9, 1-2.	0.3	0
29	Intravenous Delivery of Targeted Liposomes to Amyloid-β Pathology in APP/PSEN1 Transgenic Mice. PLoS ONE, 2012, 7, e48515.	1.1	56
30	Editorial [Hot Topic: The Complex and Multifactorial Nature of Alzheimers Disease (Guest Editors:) Tj ETQq0 0 C	) rgBT /Ove 1.4	erlock 10 Tf 50
31	Recent Insights into the Involvement of Progranulin in Frontotemporal Dementia. Current Neuropharmacology, 2011, 9, 632-642.	1.4	13
32	The enigmatic roles of microglial versus neuronal progranulin in neurological disease. Acta Neuropathologica, 2010, 119, 107-109.	3.9	3
33	Aging Is Not Associated with Proteasome Impairment in UPS Reporter Mice. PLoS ONE, 2009, 4, e5888.	1.1	22
34	Altering the Substrate Specificity of Rhll by Directed Evolution. ChemBioChem, 2009, 10, 553-558.	1.3	11
35	Progranulin: normal function and role in neurodegeneration. Journal of Neurochemistry, 2008, 104, 287-297.	2.1	114
36	Substrate-targeting Î <sup>3</sup> -secretase modulators. Nature, 2008, 453, 925-929.	13.7	277

JASON L ERIKSEN

#	Article	IF	CITATIONS
37	Biologic models of neurodegenerative disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 173-188.	1.0	3
38	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics, 2008, 17, 3631-3642.	1.4	271
39	NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development?. Trends in Pharmacological Sciences, 2007, 28, 536-543.	4.0	113
40	Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neuroscience, 2007, 8, 54.	0.8	118
41	Plaques, Tangles, and Memory Loss in Mouse Models of Neurodegeneration. Behavior Genetics, 2007, 37, 79-100.	1.4	130
42	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 2006, 442, 916-919.	13.7	1,816
43	Cysteine based novel noncompetitive inhibitors of urease(s)—Distinctive inhibition susceptibility of microbial and plant ureases. Bioorganic and Medicinal Chemistry, 2006, 14, 6737-6744.	1.4	34
44	A decade of modeling Alzheimer's disease in transgenic mice. Trends in Genetics, 2006, 22, 281-289.	2.9	266
45	An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9673-9678.	3.3	206
46	Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production. Nature Medicine, 2005, 11, 545-550.	15.2	276
47	Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors. Current Alzheimer Research, 2005, 2, 231-238.	0.7	77
48	Molecular Pathogenesis of Parkinson Disease. Archives of Neurology, 2005, 62, 353.	4.9	236
49	Gene dosage and pathogenesis of Parkinson's disease. Trends in Molecular Medicine, 2005, 11, 91-96.	3.5	95
50	Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice. Neuron, 2005, 47, 191-199.	3.8	524
51	P4-422 Mechanism of neurofibrillary degeneration in a mouse model of tauopathy and progress towards identification of a therapeutic target. Neurobiology of Aging, 2004, 25, S594.	1.5	0
52	Parkinson's disease – molecular mechanisms of disease. Drug Discovery Today Disease Mechanisms, 2004, 1, 399-405.	0.8	10
53	Effects of ethanol and ipsapirone on the development of midline raphe glial cells and astrocytes. Alcohol, 2003, 29, 157-164.	0.8	10
54	Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity. Journal of Biological Chemistry, 2003, 278, 31831-31837.	1.6	259

JASON L ERIKSEN

#	Article	IF	CITATIONS
55	NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. Journal of Clinical Investigation, 2003, 112, 440-449.	3.9	476
56	Caught in the Act. Neuron, 2003, 40, 453-456.	3.8	184
57	Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain. Journal of Biological Chemistry, 2003, 278, 30748-30754.	1.6	119
58	The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of κB Kinase, and NFκB, Do Not Reduce Amyloid Î242 Production. Journal of Biological Chemistry, 2003, 278, 31825-31830.	1.6	71
59	Effects of ethanol and 5-HT1A agonists on astroglial S100B. Developmental Brain Research, 2002, 139, 97-105.	2.1	47
60	Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease. Drug Development Research, 2002, 56, 415-420.	1.4	4
61	A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature, 2001, 414, 212-216.	13.7	1,352
62	Potential involvement of S100B in the protective effects of a serotonin-1a agonist on ethanol-treated astrocytes. Developmental Brain Research, 2001, 128, 157-164.	2.1	22
63	Astrocyte-mediated trophic support of developing serotonin neurons: effects of ethanol, buspirone, and S100B. Developmental Brain Research, 2001, 131, 9-15.	2.1	38
64	Effects of in utero ethanol exposure and maternal treatment with a 5-HT1A agonist on S100B-containing glial cells. Developmental Brain Research, 2000, 121, 133-143.	2.1	33
65	In Utero Ethanol Exposure Increases Proenkephalin, a Precursor of a Neuropeptide That Is Inhibitory to Neuronal Growth. Alcoholism: Clinical and Experimental Research, 1999, 23, 1519-1527.	1.4	7
66	Effects of Maternal Ethanol Consumption and Buspirone Treatment on Dopamine and Norepinephrine Reuptake Sites and D1 Receptors in Offspring. Alcoholism: Clinical and Experimental Research, 1997, 21, 452-459.	1.4	14